Anti-fibrotic agents such as pirfenidone, which have been shown to have considerable efficacy in the treatment of IPF in an experimental animal model [36], have been suggested to inhibit TGF-β1 signaling. Here, TGFB1 is linked to idiopathic pulmonary fibrosis.